Dr. Christopher Jones
Claim this profileSutter Medical Center Sacramento
Studies Parotid Gland Cancer
Studies Brain Tumor
26 reported clinical trials
69 drugs studied
About Christopher Jones
Education:
- Obtained an MD (Doctor of Medicine) from the University of California, Davis School of Medicine in 2010.
Experience:
- Completed a Residency in Internal Medicine at Sutter Medical Center Sacramento in 2014.
- Finished a Fellowship in Cardiology at Sutter Medical Center Sacramento in 2017.
Area of expertise
1Parotid Gland Cancer
Stage IV
p16 negative
Stage III
2Brain Tumor
IDH positive
1p/19q co-deletion positive
1p/19q loss positive
Affiliated Hospitals
Clinical Trials Christopher Jones is currently running
Lomustine + Standard Therapy
for Glioblastoma
This phase III trial compares the effect of adding lomustine to standard chemotherapy with temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. MGMT methylated tumors are more likely to respond to temozolomide chemotherapy. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Lomustine is a chemotherapy drug and in a class of medications called alkylating agents. It damages the cell's DNA and may kill tumor cells. Radiation therapy uses high energy x-ray photons to kill tumor cells and shrink tumors. Adding lomustine to standard chemotherapy with temozolomide and radiation therapy may shrink or stabilize glioblastoma.
Recruiting2 awards Phase 34 criteria
Pembrolizumab + Radiation vs Chemotherapy + Radiation
for Head and Neck Cancer
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary). Radiation therapy uses high energy radiation or protons to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Carboplatin is also in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab alone after surgery may work better than the usual approach in shrinking recurrent or primary head and neck squamous cell carcinoma.
Recruiting1 award Phase 231 criteria
More about Christopher Jones
Clinical Trial Related4 years of experience running clinical trials · Led 26 trials as a Principal Investigator · 13 Active Clinical TrialsTreatments Christopher Jones has experience with
- Cisplatin
- Radiation Therapy
- Bicalutamide
- Intensity-Modulated Radiation Therapy
- Atezolizumab
- Paclitaxel
Breakdown of trials Christopher Jones has run
Parotid Gland Cancer
Brain Tumor
Prostate Cancer
Squamous Cell Carcinoma
Oropharyngeal Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Christopher Jones specialize in?
Is Christopher Jones currently recruiting for clinical trials?
Are there any treatments that Christopher Jones has studied deeply?
What is the best way to schedule an appointment with Christopher Jones?
What is the office address of Christopher Jones?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.